MedPath

The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork

Not Applicable
Completed
Conditions
Open-angle Glaucoma
Registration Number
NCT02638181
Lead Sponsor
Lv Yingjuan
Brief Summary

This study was to assess the distinct expression of matrix metalloproteinase 13,tissue inhibitor of metalloproteinases 3, and calcium-sensing receptor, in human trabecular meshwork between normal and glaucomatous eyes.The expressions of matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3 and calcium-sensing receptor in the trabecular meshwork tissues were examined by streptavidin-peroxidase immunohistochemical staining method and western blot, and histological changes of trabecular meshwork were studied by Hematoxylin and Eosin staining.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • intraocular pressure greater than 22 mmHg with two or more medications
  • wide anterior chamber angle
  • glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect
  • visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry
Exclusion Criteria
  • the presence of any secondary form of glaucoma including exfoliation syndrome or a history of ocular trauma, etc

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
the expressions of matrix metalloproteinase 13 and calcium-sensing receptorone hour after operation
Secondary Outcome Measures
NameTimeMethod
histological changes of trabecular meshworkone hour after operation

Trial Locations

Locations (1)

Tianjin Medical University Eye Hospital

🇨🇳

Tianjin, Tianjin, China

Tianjin Medical University Eye Hospital
🇨🇳Tianjin, Tianjin, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.